Opinion|Videos|December 9, 2024
Safety Profiles of Bispecific Antibodies for RRMM
Key Takeaways
- Bispecific therapies for RRMM often lead to CRS and ICANS, necessitating careful monitoring and management to mitigate these immune-related adverse events.
- Increased infection risks are a significant concern with bispecific therapies, requiring proactive measures to prevent and manage infections in patients.
Panelists discuss how bispecific antibody therapies in relapsed/refractory multiple myeloma commonly present with cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and increased infection risks, while talquetamab specifically exhibits distinctive adverse events including nail changes, skin reactions, and oral toxicities.
Advertisement
Episodes in this series
Video content above is prompted by the following
- Provide a brief overview of typical toxicities seen with bispecific therapies for RRMM, namely CRS/ICANS and infection risks.
- Describe the unique toxicities seen with talquetamab, namely nail-related, skin-related, and oral-related toxicities.
Advertisement
Related to this article
Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
October’s hematology coverage highlighted first-line pirtobrutinib, questions about myeloma treatment duration and early intervention, and pharmacists’ roles in medication safety and access.
October’s oncology coverage highlighted new treatment options in rectal, breast, and prostate cancers, alongside longer-term survival findings and concerns about reduced-frequency immunotherapy.
Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.
ESMO 2026 lung cancer trials reshape first-line care with tarlatamab maintenance, stronger KRAS G12C results, and TROP2 ADC gains, raising pharmacy monitoring demands.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Happens Before the First Dose? 5 Steps That Shape Lung Cancer Treatment
2
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
Nicotine Vaping Linked to Lower Vascular Function in Young Adults
4
Over Half of RSV-Related Deaths in Hospitalized Adults Occur After Discharge
5